Table 3 Subgroup Analysis of Median PFS by Age, Presence or Absence of Adenocarcinoma, and Chemotherapy Combination
From: AVAiLABLE NIS – AVASTIN® in lung cancer treatment in routine oncology practice in Germany
n | Median PFS (95% CI) | |
|---|---|---|
Age [years] | ||
< 65 | 380 | 8.7 (7.4;10.1) |
65 to < 70 | 150 | 6.8 (5.8; 9.9) |
70 to < 75 | 96 | 8.0 (6.1; 8.6) |
≥ 75 | 47 | 7.4 (5.3; 20.5) |
Histologically confirmed adenocarcinoma | ||
Yes | 596 | 8.2 (7.2; 9.7) |
No / unknown | 61 | 5.0 (4.3; 9.1) |
Chemotherapy combined with bevacizumab | ||
Carboplatin/gemcitabine | 76 | 7.7 (5.8; 10.1) |
Carboplatin/pemetrexed | 108 | 8.2 (6.0; 12.5) |
Carboplatin/paclitaxel | 352 | 7.4 (6.7; 8.8) |
Cisplatin/gemcitabine | 87 | 7.0 (5.1; 10.0) |
Cisplatin/pemetrexed | 95 | 7.2 (4.6; 10.1) |
Cisplatin/vinorelbine | 59 | 7.3 (5.3; 14.2) |
Other carboplatin combinationsa | 128 | 9.0 (7.1; 11.4) |
Other cisplatin combinationsb | 64 | 9.1 (7.4; 14.2) |
Combinations not containing platinum | 87 | 8.5 (5.4; 11.5) |